Managed Healthcare Executive September 9, 2024
The researchers took what they said was a conservative approach when plugging variables such as one-time and future costs into their updated model.
It can seem like there’s almost as much research on how to pay for gene therapy treatments as there is on finding new ones, and for good reason: There’s not much use in developing a treatment that no one can afford.
Gene therapy for sickle cell disease (SCD) presents perhaps the biggest affordability challenge so far. The two gene therapies approved by the FDA last December carry list prices of roughly $2 million and $3 million. The treatments apply to a population far larger than any existing commercial gene therapy, and one-half of the estimated 100,000 people...
Today's Sponsors
Today's Sponsor